Voltage-gated potassium channels of the K V 3 subfamily, particularly K V 3.1 (encoded by KCNC1), are essential regulators of fast-spiking inhibitory interneuron activity and high-frequency neuronal firing, enabling precise control of neuronal excitability and network synchrony....
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change for current clinical practice; this is a pharmacological review of a basic-science target (KV3.1) with no approved clinical interventions yet available.
KV3.1 channel modulation represents a promising but early-stage pharmacological pathway that could eventually yield novel treatments for auditory processing deficits linked to fast-spiking interneuron dysfunction.
- 01Systematic review of drugs targeting KV3.1 voltage-gated potassium channels encoded by KCNC1.
- 02KV3.1 channels regulate fast-spiking inhibitory interneurons critical for precise auditory processing.
- 03No currently approved clinical therapies targeting this channel for auditory indications.
- 04Findings are primarily relevant to preclinical and translational auditory neuroscience research.
- 05Could inform future drug development for auditory processing disorders.
Pharmacological modulation of KV3.1 channels can influence fast-spiking inhibitory interneuron activity relevant to auditory processing.
studypartially supported- PMID
- 42631129
- DOI
- 10.3389/fphar.2026.1821275.
- Journal
- Frontiers in Pharmacology
- Publication type
- systematic_review
- Evidence level
- 1a
- Population
- Preclinical and pharmacological studies of KV3.1 channel modulation
- Intervention
- Pharmacological agents modulating KV3.1 (KCNC1) voltage-gated potassium channels
Primary outcomes
Pharmacological strategies for KV3.1 modulation; Implications for auditory processing via fast-spiking interneuron regulation